David Shaw’s Kymera Therapeutics KYMR Stock Holding History

David Shaw’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$321K	Buy	+2,800	New	+$241K	﹤0.01%	4385
2025 Q1	–	Sell	-82,578	Closed	-$3.32M	–	4512
2024 Q4	$3.32M	Sell	82,578 -105,619	-56%	-$4.77M	﹤0.01%	2313
2024 Q3	$8.91M	Sell	188,197 -107,375	-36%	-$4.74M	0.01%	1498
2024 Q2	$8.82M	Buy	295,572 +227,810	+336%	+$7.89M	0.01%	1410
2024 Q1	$2.72M	Buy	+67,762	New	+$2.42M	﹤0.01%	2387
2023 Q2	–	Sell	-27,032	Closed	-$801K	–	4396
2023 Q1	$801K	Buy	27,032 +13,553	+101%	+$437K	﹤0.01%	3307
2022 Q4	$336K	Buy	13,479 +2,662	+25%	+$71K	﹤0.01%	4042
2022 Q3	$235K	Buy	+10,817	New	+$285K	﹤0.01%	4406
2021 Q2	–	Sell	-14,645	Closed	-$569K	–	4889
2021 Q1	$569K	Sell	14,645 -16,947	-54%	-$1.02M	﹤0.01%	3449
2020 Q4	$1.96M	Buy	+31,592	New	+$1.54M	﹤0.01%	2569

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

David Shaw's KYMR Position: Q2 2026 in Review

David Shaw opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 2,800 shares worth $321K. The stake represents ﹤0.01% of the portfolio and ranks #4385 among its holdings. This is a return to the name: David Shaw previously reported a position in KYMR as recently as Q4 2024.

David Shaw first reported a position in KYMR in Q4 2020 and has held it in 10 quarters since. The position peaked at $8.91M in Q3 2024. 273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

David Shaw held 2,800 shares of Kymera Therapeutics worth $321K as of Q2 2026.
Kymera Therapeutics was a new David Shaw position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4385 holding.
David Shaw first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 10 quarters since.
David Shaw's Kymera Therapeutics position peaked at $8.91M in Q3 2024.
273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.